Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815418 | 0.83 | DRD2 (0.40) | KMT2AKCNN4POLBTRPV6HSD11B1 | |
| SCHEMBL14815366 | 0.83 | DRD2 (0.40) | KMT2AKCNN4POLBTRPV6HSD11B1 | |
| SCHEMBL14814948 | 0.78 | KMT2A (0.41) | KMT2AKCNN4POLBMEN1CCR2 | |
| SCHEMBL14815147 | 0.77 | KMT2A (0.39) | KMT2AKCNN4POLBMEN1HCRTR1 | |
| SCHEMBL14815117 | 0.77 | KMT2A (0.39) | KMT2AKCNN4POLBMEN1HCRTR1 | |
| SCHEMBL15794124 | 0.76 | KMT2A (0.40) | KMT2AKCNN4POLBMEN1HSD11B1 | |
| SCHEMBL15794255 | 0.76 | KMT2A (0.40) | KMT2AKCNN4POLBMEN1HSD11B1 | |
| SCHEMBL15793870 | 0.76 | KMT2A (0.40) | KMT2AKCNN4POLBMEN1HSD11B1 | |
| SCHEMBL15793990 | 0.76 | KMT2A (0.40) | KMT2AKCNN4POLBMEN1HSD11B1 | |
| SCHEMBL15799689 | 0.76 | KMT2A (0.40) | KMT2AKCNN4POLBMEN1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | KMT2A 2999/4885KCNN4 13/4885POLB 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.